Working… Menu

Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02554396
Recruitment Status : Completed
First Posted : September 18, 2015
Last Update Posted : October 23, 2017
Information provided by (Responsible Party):
Presbyopia Therapies, LLC

Brief Summary:
This is a one-day, randomized, double-masked, single-center evaluation of the efficacy and safety of PRX-100 ophthalmic solution compared to placebo in 20 subjects (randomized 4:1, PRX-100:placebo) to evaluate the safety of PRX-100 and the magnitude and duration of effects on improving near-vision acuity.

Condition or disease Intervention/treatment Phase
Presbyopia Drug: PRX-100 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia
Study Start Date : September 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Experimental: PRX-100
PRX-100 ophthalmic solution
Drug: PRX-100
ophthalmic solution

Placebo Comparator: Placebo
saline solution
Drug: Placebo
saline ophthalmic solution

Primary Outcome Measures :
  1. binocular assessment of uncorrected near visual acuity [ Time Frame: day 1 ]

Secondary Outcome Measures :
  1. pupil diameter [ Time Frame: day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. be 45-59 years of age of either sex and any race or ethnicity;
  2. be able and willing to provide written informed consent and sign HIPAA form prior to any study procedure being performed;
  3. be able and willing to follow all instructions and attend all study visits;
  4. have a negative urine pregnancy test at Visit 1, if female of childbearing potential (those who have experienced menarche and who are not surgically sterilized [bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or post-menopausal [12 months after last menses]) and must use adequate birth control throughout the study period. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control;
  5. be an early to moderate presbyope
  6. be able and willing to avoid all disallowed medication(s) for the appropriate washout period and during the study without significant risk to the subject (see exclusion 15).

Exclusion Criteria:

  1. have known contraindications or sensitivity to the use of any of the study medications(s) or their components;
  2. have an active ocular infection (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye. Mild dry eye controlled with artificial tears and mild blepharitis controlled with lid scrubs is allowed;
  3. have had surgical intervention (ocular or systemic) within 6 months prior to Visit 1, or planned surgical intervention within 30 days thereafter;
  4. have had refractive surgery in the past;
  5. have dry eye history defined as either current use of Restasis®, past history of insertion of punctual plugs, or daily use of artificial tears more than one drop per day;
  6. have a known history of retinal detachment, diabetic retinopathy, or progressive retinal disease;
  7. have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg, or be on any type of intraocular hypertension or any type of glaucoma topical treatment at Visit 1;
  8. have red-green color blindness confirmed by Ishihara test during baseline procedures;
  9. have an inability or refuse to discontinue contact lens wear 7 days prior to the study visit and during the study visit;
  10. have used an investigational drug or device within 30 days of starting the study or be concurrently enrolled in another investigational drug or device study;
  11. be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy; tests positive to a urine pregnancy test at Visit 1; or refuses to use an adequate method of contraception for the duration of the study;
  12. have a condition or a situation, which in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation, including but not limited to unstable: cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease;
  13. use any of the following disallowed medications during the 2 weeks (14 days) prior to Visit 1 and during the study:

    • narcotic (opiate class) pain medication (e.g. codeine, oxycontin, Vicodin®, Tramadol®)
    • bladder medication (e.g. urecholine, bethanechol®)
    • antipsychotics
    • antidepressants
    • anticholinergics (e.g. atropine, belladonna, benztropine, dicyclomine, donepezil, hyoscyamine, propantheline, scopolamine, trihexphenidyl
    • dry mouth (e.g. salagen®), Evoxac®)
    • antihistamines or decongestants
    • artificial tear use of more than 1 drop per day
    • diagnostic medications required by the protocol are allowed;
  14. report of recreational drug use (e.g. marijuana, methadone, heroin, cocaine).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02554396

Layout table for location information
United States, Massachusetts
Andover Eye Associates
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Presbyopia Therapies, LLC

Layout table for additonal information
Responsible Party: Presbyopia Therapies, LLC Identifier: NCT02554396     History of Changes
Other Study ID Numbers: PRX100.FDAII
First Posted: September 18, 2015    Key Record Dates
Last Update Posted: October 23, 2017
Last Verified: October 2017
Keywords provided by Presbyopia Therapies, LLC:
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions